Target intelligence / Profile preview

Human immunodeficiency virus 1 envelope glycoprotein gp120 C5 region (gp120 C5)

Target
gp120 C5
Molecular classification
Viral protein, Envelope glycoprotein subunit
01

Overview

The HIV-1 gp120 C5 region is the C-terminal domain of the surface glycoprotein gp120, which plays a critical role in the non-covalent association with the transmembrane glycoprotein gp41 (RCSB PDB 1MEQ; Guilhaudis et al., 2002). This region, along with the N-terminal C1 region, forms a key part of the gp120/gp41 protein-protein interface within the functional envelope (Env) trimer. The stability of this interface is essential for maintaining the virus in its pre-fusion state and for the subsequent conformational transitions triggered by CD4 and co-receptor binding that lead to viral-host membrane fusion (NIH, 2021). Because of its conserved nature and functional importance, the C5 region and the broader gp120/gp41 interface have emerged as significant targets for broadly neutralizing antibodies (bNAbs) such as 35O22 and VRC44 (Huang et al., 2014; Cale et al., 2024). These agents work by stabilizing the Env trimer and sterically hindering the structural rearrangements necessary for infection. Therapeutic challenges include the potential for viral escape through mutations at the interface and the risk of autoimmune responses due to molecular mimicry between the C5 region and human leukocyte antigen (HLA) class I molecules (Eur J Immunol, 1993).

Other names
C5 domain of gp120gp120 C-terminal regiongp120/gp41 interfaceC5 region of HIV-1 gp120gp120-gp41 quaternary interface
02

Mechanism of action

Inhibition of HIV-1 entry by binding to the gp120/gp41 interface, stabilizing the pre-fusion envelope trimer and preventing the conformational changes required for membrane fusion.

03

Biological functions

Viral entryMembrane fusionProtein-protein interactionConformational change
04

Disease associations

InfectionHIV-1 infectionAIDS
05

Safety considerations

Viral resistance through mutations at the interfaceMolecular mimicry with HLA class I moleculesImmune evasion through conformational masking and glycosylation
06

Interacting drugs

35O22

6 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-cell countHIV-1 envelope sequence (resistance mutations)

Beyond the preview

Go deeper on Human immunodeficiency virus 1 envelope glycoprotein gp120 C5 region (gp120 C5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus 1 envelope glycoprotein gp120 C5 region (gp120 C5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call